Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharmacol ; 973: 176537, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38604546

ABSTRACT

Previous studies have shown that all kinin system is constitutively expressed in the normal and inflamed skin, with a potential role in both physiological and pathological processes. However, the understanding regarding the involvement of the kinin system in skin pigmentation and pigmentation disorders remains incomplete. In this context, the present study was designed to determine the role of kinins in the Monobenzone (MBZ)-induced vitiligo-like model. Our findings showed that MBZ induces higher local skin depigmentation in kinin receptors knockout mice (KOB1R, KOB2R and KOB1B2R) than in wild type (WT). Remarkably, lower levels of melanin content and reduced ROS generation were detected in KOB1R and KOB2R mice treated with MBZ. In addition, both KOB1R and KOB2R show increased dermal cell infiltrate in vitiligo-like skin, when compared to WT-MBZ. Additionally, lack of B1R was associated with greater skin accumulation of IL-4, IL-6, and IL-17 by MBZ, while KOB1B2R presented lower levels of TNF and IL-1. Of note, the absence of both kinin B1 and B2 receptors demonstrates a protective effect by preventing the increase in polymorphonuclear and mononuclear cell infiltrations, as well as inflammatory cytokine levels induced by MBZ. In addition, in vitro assays confirm that B1R and B2R agonists increase intracellular melanin synthesis, while bradykinin significantly enhanced extracellular melanin levels and proliferation of B16F10 cells. Our findings highlight that the lack of kinin receptors caused more severe depigmentation in the skin, as well as genetic deletion of both B1/B2 receptors seems to be linked with changes in levels of constitutive melanin levels, suggesting the involvement of kinin system in crucial skin pigmentation pathways.


Subject(s)
Melanins , Skin Pigmentation , Animals , Skin Pigmentation/drug effects , Mice , Melanins/metabolism , Melanins/biosynthesis , Mice, Knockout , Receptor, Bradykinin B1/metabolism , Receptor, Bradykinin B1/genetics , Cytokines/metabolism , Vitiligo/metabolism , Vitiligo/pathology , Receptor, Bradykinin B2/metabolism , Skin/metabolism , Skin/drug effects , Skin/pathology , Reactive Oxygen Species/metabolism , Mice, Inbred C57BL , Humans , Male
2.
J Invest Dermatol ; 143(1): 142-153.e10, 2023 01.
Article in English | MEDLINE | ID: mdl-36049541

ABSTRACT

Growing evidence indicates that transient receptor potential (TRP) channels contribute to different forms of pruritus. However, the endogenous mediators that cause itch through transient receptor potential channels signaling are poorly understood. In this study, we show that genetic deletion or pharmacological antagonism of TRPV4 attenuated itch in a mouse model of psoriasis induced by topical application of imiquimod. Human psoriatic lesions showed increased expression of several microRNAs, including the miR-203b-3p, which induced a calcium ion response in rodent dorsal root ganglion neurons and scratching behavior in mice through 5-HTR2B activation and the protein kinase C‒dependent phosphorylation of TRPV4. Computer simulation revealed that the miR-203b-3p core sequence (GUUAAGAA) that causes 5-HTR2B/TRPV4-dependent itch targets the extracellular side of 5-HTR2B by interacting with a portion of the receptor pocket consistent with its activation. Overall, we reveal the unconventional pathophysiological role of an extracellular microRNA that can behave as an itch promoter through 5-HTR2B and TRPV4.


Subject(s)
MicroRNAs , Pruritus , Receptor, Serotonin, 5-HT2B , TRPV Cation Channels , Animals , Humans , Mice , Computer Simulation , Ganglia, Spinal , Mice, Inbred C57BL , MicroRNAs/genetics , MicroRNAs/metabolism , Pruritus/chemically induced , Pruritus/genetics , Pruritus/metabolism , TRPV Cation Channels/genetics , TRPV Cation Channels/metabolism , Receptor, Serotonin, 5-HT2B/genetics , Receptor, Serotonin, 5-HT2B/metabolism
3.
J Ethnopharmacol ; 259: 112840, 2020 Sep 15.
Article in English | MEDLINE | ID: mdl-32268204

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Baccharis dracunculifolia (Asteraceae) is a commonly used plant in traditional medicine known as "alecrim-do-campo". Popularly it has been used as an immunostimulant, antibiotic, anti-inflammatory among other applications. So far, only a few studies have investigated the B. dracunculifolia anti-inflammatory effect and none has investigated the effectiveness of essential oil on skin diseases. AIM OF THE STUDY: The study aimed at evaluating the topical anti-inflammatory activity of B. dracunculifolia essential oil (BdEO) in mice models of acute and chronic skin inflammation. MATERIALS AND METHODS: BdEO was obtained from leaves and it was analyzed with Gas Chromatograph. Topical anti-inflammatory activity of BdEO (0.1, 0.3 and 1.0 mg/ear) was evaluated in Arachidonic Acid or TPA-induced acute and chronic skin inflammation in mice. Parameters such edema, cell migration and keratinocytes proliferation were evaluated. In addition, safety and a possible mechanism of action for BdEO essential oil were also investigated. RESULTS: Our results indicate that mainly terpenoids compounds compose BdEO. In addition, topical treatment with BdEO inhibited inflammatory parameters in both acute and chronic models of skin inflammation. This protective effect was associated with reduced edema formation, smaller cellular influx into the inflamed tissue and reduction of keratinocytes hyperproliferation. Although BdEO appears to exert its anti-inflammatory effect through a corticosteroid pathway, no local or systemic side effects were observed. CONCLUSION: Taken together, the present results showed that the essential oil obtained by hydrodistillation from B. dracunculifolia leaf samples exhibit remarkable topical anti-inflammatory properties. Therefore, our study demonstrated evidence for BdEO topical anti-inflammatory efficacy and safety, suggesting that it could be considered for developing of a new phytotherapeutic formulation as treatment for skin diseases.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Baccharis/chemistry , Drug Eruptions/drug therapy , Oils, Volatile/pharmacology , Animals , Anti-Inflammatory Agents/chemistry , Drug Eruptions/pathology , Edema/chemically induced , Edema/drug therapy , Epidermis/pathology , Female , Lymphatic System/drug effects , Mice , Oils, Volatile/chemistry , Plant Extracts/pharmacology , Plant Leaves/chemistry , Receptors, Glucocorticoid/metabolism
4.
J Ethnopharmacol ; 254: 112708, 2020 May 23.
Article in English | MEDLINE | ID: mdl-32142866

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Popularly used in India and sub-Hymalaian region, Moringa oleifera (Moringaceae) is associated with healing properties demonstrated in its use as treatment of acute and chronic skin diseases. Our study aimed at investigating the effects of M. oleifera seed oil (MOSO) in animal models for inflammatory and hyperproliferative skin conditions. MATERIALS AND METHODS: MOSO was analyzed using gas chromatography/mass spectrometry. The anti-inflammatory and anti-hyperproliferative effects of treatment with either MOSO or oleic acid (OA), its main constituent, was evaluated. Acute and chronic inflammation was induced by applying 12-O-Tetradecanoylphorbol-13-acetate (TPA) and acute inflammation with either Arachidonic Acid (AA) or Phenol onto the ear of Swiss mice. Systemic activity and the influence of glucocorticoid receptors (GC) was also evaluated. RESULTS: Topical application of MOSO and OA inhibited ear edema caused by TPA, and Phenol. Only MOSO inhibited ear edema induced by AA. Neutrophil migration was also inhibited by treatment with MOSO. Topical application of MOSO, but not OA, significantly reduced chronic skin inflammation and epidermal hypertrophy induced by multiple TPA applications. Pre-treatment with GC antagonist mifepristone reversed the anti-inflammatory effect of MOSO and OA on the TPA model. Repeated administration of MOSO show a similar effect to dexamethasone on thymus weight, though MOSO did not present any influence on skin thickness, as well as in the weight of the spleen, adrenal gland and lymph node. CONCLUSION: The results suggest that MOSO is effective as a treatment for skin diseases that rely on keratinocyte hyperproliferation. OA is also effective in acute inflammation. Both MOSO and OA depend on GC activation for anti-inflammatory effect but do not exhibit the same adverse effects seen in topical treatment with dexamethasone. We hereby evidence the use of MOSO as a topical anti-inflammatory agent in inflammatory skin diseases, thus, expanding its therapeutic potential.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Dermatitis, Contact/drug therapy , Moringa oleifera , Oleic Acid/therapeutic use , Plant Oils/therapeutic use , Adrenal Glands/drug effects , Animals , Atrophy/drug therapy , Atrophy/metabolism , Cell Proliferation/drug effects , Dermatitis, Contact/metabolism , Edema/drug therapy , Edema/metabolism , Female , Irritants , Keratinocytes/drug effects , Lymph Nodes/drug effects , Mice , Receptors, Glucocorticoid/metabolism , Seeds , Skin/drug effects , Skin/pathology , Spleen/drug effects , Tetradecanoylphorbol Acetate , Thymus Gland/drug effects
5.
J Ethnopharmacol ; 254: 112709, 2020 May 23.
Article in English | MEDLINE | ID: mdl-32109543

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Cyperus rotundus L. (Cyperaceae) is considered one of the most widely distributed plant species in the world, especially in tropical and subtropical regions. In addition, it is commonly used in India, China and Japan in traditional medicine to treat different diseases, including dermatitis and other skin disorders. AIM OF THE STUDY: To investigate the topical anti-inflammatory activity of C. rotundus rhizome ethanolic extract in models of acute and chronic dermatitis. MATERIALS AND METHODS: Phytochemical analysis was carried out using High-performance liquid chromatography-ultraviolet detection (HPLC/UV) to determine the presence of quercetin and chlorogenic acid in C. rotundus extract. Topical anti-inflammmatory effects of C. rotundus extract were evaluated on arachidonic acid (AA) and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation in mice. Skin biopsies were collected and submitted to histological and enzymatic analysis to evaluate the C. rotundus effect in leukocyte migration into inflamed tissue. Antiproliferative activity of C. rotundus was confirmed by PCNA immunostained cell analysis. Systemic and possible adverse effects of topical treatment with C. rotundus were evaluated by the skin atrophy and same organ weights. In addition, the glucocorticoid receptor (GR) antagonist mifepristone was used to investigate possible GR-mediated mechanisms of action. RESULTS: The phytochemical analysis show that C. rotundus ethanol extract contains 45 µg/g of chlorogenic acid. Topical treatment with C. rotundus extract reduced ear edema and cellular infiltrate in acute and chronic skin inflammation models. Moreover, mice topically treated with C. rotundus exhibited decrease in TPA-induced keratinocyte hyperproliferation. Relevantly, topical treatment with C. rotundus did not caused skin atrophy or changes in lymphoid organ weight. The anti-inflammatory effect of C. rotundus was not influenced by the GR antagonist. CONCLUSION: The results here demonstrate for the first time the topical anti-inflammatory and antiproliferative efficacy of C. rotundus extract, suggesting that the extract could be a potential new therapeutic tool for the treatment of inflammatory skin disorders.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Cyperus , Dermatitis, Contact/drug therapy , Plant Extracts/therapeutic use , Adrenal Glands/drug effects , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , Arachidonic Acid , Atrophy/drug therapy , Cell Proliferation/drug effects , Edema/drug therapy , Edema/metabolism , Female , Irritants , Keratinocytes/drug effects , Lymph Nodes/drug effects , Mice , Phytochemicals/analysis , Phytochemicals/therapeutic use , Phytotherapy , Plant Extracts/chemistry , Plant Extracts/pharmacology , Rhizome , Skin/drug effects , Skin/pathology , Spleen/drug effects , Tetradecanoylphorbol Acetate , Thymus Gland/drug effects
6.
Biomed Pharmacother ; 104: 151-157, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29772435

ABSTRACT

Psoriasis is a complex inflammatory and hyperproliferative skin disease. The pathogenesis and mechanisms involved are not completely understood, which makes treatment a difficult issue. Angiotensin II, the most active peptide of the renin-angiotensin system, seems to be involved in processes related to psoriasis pathogenesis, such as inflammation and cell proliferation. The aim of this study was to investigate the influence of renin inhibition on inflammation parameters and keratinocyte proliferation in a mouse model of chronic skin inflammation induced by croton oil. Aliskiren had anti-inflammatory effects by reducing levels of tumor necrosis factor-α and interleukin -6, and by inhibiting myeloperoxidase activity. Aliskiren also showed antiproliferative activity by reducing epidermal hyperplasia and proliferating cell nuclear antigen levels. Aliskiren treatment did not induce alterations in the cardiovascular system, normal skin thickness, and organ weight. These results suggest that aliskiren could be a valuable tool to be incorporated in the treatment of hyperproliferative and inflammatory skin disorders such as psoriasis.


Subject(s)
Amides/pharmacology , Antihypertensive Agents/pharmacology , Fumarates/pharmacology , Skin Diseases/drug therapy , Angiotensin II/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Cardiovascular System/drug effects , Cardiovascular System/metabolism , Disease Models, Animal , Female , Inflammation/drug therapy , Inflammation/metabolism , Keratinocytes/drug effects , Keratinocytes/metabolism , Mice , Psoriasis/drug therapy , Psoriasis/metabolism , Renin/metabolism , Renin-Angiotensin System/drug effects , Skin Diseases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...